both in symptomatology and risk assessment, and acknowledged the potential increased role of aggressive
medical management as primary therapy in this highrisk group.
7. Neurologically asymptomatic patients deemed “high
risk” for CEA should be considered for primary medical
management. CEA can be considered in these patients
only with evidence that perioperative morbidity and
mortality is ⬍3%. CAS should not be performed in these
patients except as part of an ongoing clinical trial
(G